MedTrace Logo

Retrospective Data Collection Study in Patients With Macular Oedema Receiving OZURDEX®

NCT02181530 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 43

Last updated 2015-05-25

Study results available
· View outcomes & findings →

Summary

This study will use retrospective data to evaluate the safety and efficacy of OZURDEX® (dexamethasone intravitreal implant 0.7 mg) in the treatment of macular oedema due to retinal vein occlusion (RVO) in clinical practice. No intervention will be administered as part of this study.

Conditions

  • Macular Edema
  • Retinal Vein Occlusion

Interventions

OTHER

No Intervention

No treatment (intervention) is being administered as part of this study.

Sponsors & Collaborators

  • Allergan

    lead INDUSTRY

Principal Investigators

  • Medical Director · Allergan

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-07-31
Primary Completion
2014-10-31
Completion
2014-10-31

Countries

  • Poland

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02181530 on ClinicalTrials.gov